E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Prophylaxis of migraine headache |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to estimate the dose-response and dose-safety relationships for GW274150 in the prophylaxis of migraine. |
|
E.2.2 | Secondary objectives of the trial |
•To explore efficacy of each dose of GW274150 compared with placebo using various clinical endpoints in the prophylaxis of migraine headaches
•To investigate the safety and tolerability of GW274150 in the prophylaxis of migraine headaches
•To evaluate the pharmacokinetics of GW274150
•To evaluate the relationship between systemic GW274150 exposure and the prophylaxis of migraine headaches
•To evaluate the relationship between systemic GW274150 exposure and safety and tolerability endpoints in migraineurs
•To explore potential relationships between genetic variants and GW274150 efficacy endpoints
•To determine the change in migraine-related quality of life, treatment satisfaction and productivity in subjects treated prophylactically with oral daily GW274150 compared to subjects treated prophylactically with placebo
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
Subjects, otherwise healthy, suffering from migraine with or without aura, according to 2004 IHS criteria 1.1 and 1.2.1 (see Appendix 2 of protocol).
Subject has had migraine for at least one year, and the age of onset was prior to 50 years.
Subject has consistent migraine headache over time (i.e., incidence and severity).
Subject had at least 3 migraine headache attacks but less than 15 headache days(migraine or non-migraine) per month in each of the three months prior to the Screening Visit and maintains this requirement during the baseline period.
Subject is able to distinguish migraine headache attacks as discreet attacks from other headaches (i.e., tension-type headaches).
No clinically significant abnormality identified on the medical or laboratory evaluation, including 12–lead ECG. A subject with a clinical abnormality or laboratory parameters outside the reference range may be included only if the Investigator considers that the finding will not introduce additional risk factors and will not interfere with the study procedures.
A female is eligible to enter and participate in this study if she is of: a) non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal (>1 year since last menstrual cycle), had a documented tubal ligation or is surgically sterilized); or, b) child-bearing potential, has a negative pregnancy test (urine) at screen, and agrees to one of the following:
1. Complete abstinence from intercourse from 2 weeks prior to administration of the investigational product, throughout the Treatment Period and for a minimum of one week after completion or premature discontinuation from investigational product; or
2. Consistent and correct use of an acceptable method of birth control as outlined in the protocol.
|
|
E.4 | Principal exclusion criteria |
1. As a result of the medical interview, physical examination or screening investigations, that the Investigator or appropriately qualified designee considers the subject unfit for the study. 2. Subject has headache for 15 days per month or greater in any of the three months (90 days) preceding the Screening Visit. 3. Subject has history of alcohol, substance or drug abuse within the last year. 4. Subject has taken a migraine prophylactic medication within 1 month of the Screening Visit. 5. Subject uses an opiate as first line acute treatment for migraine attacks. 6. Subject has history of ergotamine, triptan, opioid, or combination medication intake on ≥10 days per month on a regular basis for ≥3 months. 7. Subject has history of simple analgesic intake on ≥15 days per month for ≥3months. 8. Subject has failed two or more adequate treatments of migraine prophylaxis -where failure is defined as a lack of efficacy with a treatment duration of at least 8 weeks or withdrawal of treatment due to treatment intolerance. 9. Subject has uncontrolled hypertension at the Screening Visit, defined as persistent (after 3 readings) systolic blood pressure >140mmHg or diastolic blood pressure >90mmHg; measured after 10 minutes of rest. 10. Subject is taking cyclosporine and/or aminoglycosides. 11. Evidence of renal impairment - calculated creatinine clearance < 60ml/min (Cockroft-Gault formula, Appendix 4) or clinically relevant finding (more than 1+ protein or blood) on urinalysis (including microscopy). 12. Subject has a history of drug or other allergy which, in the opinion of the Investigator, makes the subject unsuitable for participation in the study. 13. Subject is concurrently participating in another clinical study or investigational drug trial or has participated within the previous 3 months or is planning to participate in another drug or device study at any time during this study (screening through followup) or has had previous exposure to GW274150 in Part 1 of the study. 14. Subject is felt to be at risk of non-compliance (for taking study medication or for completing the electronic diary (e-diary)), in the Investigator’s opinion. 15. Pregnant or nursing women. 16. History of, or risk factors for, HIV, Hepatitis B and Hepatitis C. 17. Past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to history of liver or renal disease in the 6 months prior to screening. 18. Clinically significant abnormalities in safety laboratory analysis at the Screening Visit. Particularly any liver function test (including ALT, AST and ALP) or pancreatic function test (pancreatic amylase or lipase) >1.5 x upper limit normal (ULN) at the Screening Visit. 19. The subject is not covered by social security (requirement for subjects recruited in France)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is the occurrence of a migraine headache day on each day during the 4-week baseline period and the 12-week treatment period, where a migraine headache day is defined as a calendar day with any occurrence of migraine headache pain of at least 30 minutes in duration. This analysis will be conducted after Part 1 and Part 2 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 4 |